ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅, ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΈ ΠΈΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΏΡΠΎΡΠ΅ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°
![ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ: ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅, ΠΈΠΌΠΌΡΠ½ΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΈ ΠΈΡ
Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΏΡΠΎΡΠ΅ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°](https://gugn.ru/work/8738205/cover.png)
Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π²ΡΠ΄Π΅Π»Π΅Π½Ρ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½Ρ ΠΊ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΠΎ-Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ ΡΠΏΠΈΡΠΎΠΏΠ°ΠΌ ΠΌΠΎΠ»Π΅ΠΊΡΠ»Ρ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°. ΠΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΠΎΠ±Π»Π°Π΄Π°ΡΡ ΠΏΠ΅ΡΠ΅ΠΊΡΡΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½Ρ ΠΈ ΠΏΡΠΎΡΡΠΎΠΌΠ±ΠΈΠ½Ρ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΏΠΈΡΠΎΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ
- ΠΠΠΠΠ 1. ΠΠΠΠΠ ΠΠΠ’ΠΠ ΠΠ’Π£Π Π«
- 1. 1. ΠΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌ ΡΠ²ΡΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ
- 1. 2. ΠΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ Π±Π΅Π»ΠΊΠ°ΠΌ-ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠ²ΡΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ
- 1. 3. ΠΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ Π±Π΅Π»ΠΊΠ°ΠΌ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ
- ΠΠΠΠΠ 2. ΠΠΠ’ΠΠ ΠΠΠΠ« Π ΠΠΠ’ΠΠΠ«
- 2. 1. Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°
- 2. 2. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Glu-, /??Ρ-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΈ Π΅Π³ΠΎ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ
- 2. 2. 1. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Glu-, Π₯^-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°
- 2. 2. 2. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΡΡΠΎΡΡ ΠΈ Π³ΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°
- 2. 2. 3. ΠΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Glu-, ΒΏ^-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° Π΄Π»Ρ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ Π°ΡΡΠΈΠ½Π½ΠΎΠ³ΠΎ ΡΠΎΡΠ±Π΅Π½ΡΠ° ΠΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½-Π‘Π΅ΡΠ°ΡΠΎΠ·Π°
- 2. 3. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 2. 3. 1. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΌΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ IgG
- 2. 3. 2. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΈΡΡΠΎΡΡ ΠΈ Π³ΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ IgG
- 2. 3. 3. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 2. 3. 4. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π²ΡΡ ΠΎΠ΄Π° Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘ ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ Π΄ΠΎΠ½ΠΎΡΠΎΠ²
- 2. 4. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ²ΠΎΠΉΡΡΠ² Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ
Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 2. 4. 1. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π°Π½ΡΠΈΠ³Π΅Π½Π½ΠΎΠΉ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΠΈ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 2. 4. 2. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΏΠΈΡΠΎΠΏΠ½ΠΎΠΉ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΠΈ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 2. 4. 3. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠ΅ΡΠ΅ΠΊΡΡΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ Ρ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 2. 5. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG Π½Π° Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, Zys-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°
- 2. 5. 1. ΠΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, Lys- ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΌΠΎΡΠ΅Π²ΠΎΠΉ ΡΡΠΎΠΊΠΈΠ½Π°Π·ΠΎΠΉ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 2. 5. 2. ΠΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, Lys- ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΌΠΎΡΠ΅Π²ΠΎΠΉ ΡΡΠΎΠΊΠΈΠ½Π°Π·ΠΎΠΉ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 2. 5. 3. ΠΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, /^Ρ-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΡΠΊΠ°Π½Π΅Π²ΡΠΌ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡΠΎΠΌ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ ΠΌΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠ±ΡΠΈΠ½Π°
- 2. 5. 4. ΠΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, Lys- ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΡΠΊΠ°Π½Π΅Π²ΡΠΌ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡΠΎΠΌ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ ΠΌΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠ±ΡΠΈΠ½Π° ΠΈ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 2. 5. 5. ΠΠΈΠ΄ΡΠΎΠ»ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠΌ Ρ ΡΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΠ΅ΠΏΡΠΈΠ΄Π½ΠΎΠ³ΠΎ ΡΡΠ±ΡΡΡΠ°ΡΠ° S
- 2. 5. 6. ΠΠΈΠ΄ΡΠΎΠ»ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠΌ S2251 Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 3. 1. ΠΠ΅ΡΠΎΠ΄ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘
- 3. 2. ΠΠ½Π°Π»ΠΈΠ· ΠΈΠΌΠΌΡΠ½ΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠΎΡΡ ΠΈ Π³ΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ
Π±Π΅Π»ΠΊΠΎΠ²
- 3. 2. 1. ΠΠ½Π°Π»ΠΈΠ· ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠΎΡΡ, Π³ΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ ΠΈ Π½Π°ΡΠΈΠ²Π½ΠΎΡΡΠΈ Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ Glu-, ?Ρ.Ρ-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°
- 3. 2. 2. ΠΠ½Π°Π»ΠΈΠ· ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠΎΡΡ ΠΈ Π³ΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° IgG
- 3. 2. 3. ΠΠ½Π°Π»ΠΈΠ· ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠΎΡΡ ΠΈ Π³ΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 3. 3. ΠΠΌΠΌΡΠ½ΠΎΡ
ΠΈΠΌΠΈΡΡΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 3. 3. 1. Π‘ΠΎΠ·Π΄Π°Π½ΠΈΠ΅ Π΅Π΄ΠΈΠ½ΠΎΠ³ΠΎ ΠΏΡΠ»Π° Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 3. 3. 2. ΠΠ½ΡΠΈΠ³Π΅Π½Π½Π°Ρ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 3. 3. 3. ΠΠΏΠΈΡΠΎΠΏΠ½Π°Ρ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΠΠΠ‘Π Π½Π° ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» Ρ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½ΠΎΠΌ
- 3. 3. 4. ΠΠΏΠΈΡΠΎΠΏΠ½Π°Ρ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΡΡΡΠ΅ΠΏΡΠΎΠΊΠΈΠ½Π°Π·Ρ Π½Π° ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» Ρ ΠΈΠΌΠΌΠΎΠ±ΠΈΠ»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠΌ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½ΠΎΠΌ
- 3. 3. 5. ΠΠ΅ΡΠ΅ΠΊΡΡΡΡΠ½Π°Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΠ³
- 3. 4. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΠ³ Π½Π° Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, Lys- ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°
- 3. 4. 1. ΠΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, /^ΒΏ-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΌΠΎΡΠ΅Π²ΠΎΠΉ ΡΡΠΎΠΊΠΈΠ½Π°Π·ΠΎΠΉ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΠ³
- 3. 4. 2. ΠΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, Zys-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΡΠΊΠ°Π½Π΅Π²ΡΠΌ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡΠΎΠΌ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° Π² ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»
- 3. 5. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΠ³ Π½Π° Π³ΠΈΠ΄ΡΠΎΠ»ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠΌ Ρ ΡΠΎΠΌΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠ±ΡΡΡΠ°ΡΠ° S
- 4. 1. ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ Π² ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ
- 4. 2. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΌΠ΅ΡΠΎΠ΄Π° Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘
- 4. 3. ΠΠΌΠΌΡΠ½ΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 4. 3. 1. ΠΠ½ΡΠΈΠ³Π΅Π½Π½Π°Ρ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 4. 3. 2. ΠΠΏΠΈΡΠΎΠΏΠ½Π°Ρ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 4. 3. 3. ΠΠ΅ΡΠ΅ΠΊΡΠ΅ΡΡΠ½Π°Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
- 4. 4. ΠΠ»ΠΈΡΠ½ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ Π½Π° Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ Glu-, Xys-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°
- 4. 5. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ
ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅, ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΈ ΠΈΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΏΡΠΎΡΠ΅ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ.
Π€ΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΠΊΡΠΎΠ²ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π°ΠΆΠ½ΡΠΌ Π·Π°ΡΠΈΡΠ½ΡΠΌ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠΌ ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ². Π ΠΎΡΠ½ΠΎΠ²Π΅ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ Π»Π΅ΠΆΠΈΡ ΡΠ΅Π°ΠΊΡΠΈΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° Ρ ΠΏΡΠ΅Π²ΡΠ°ΡΠ΅Π½ΠΈΠ΅ΠΌ Π΅Π³ΠΎ Π² Π°ΠΊΡΠΈΠ²Π½ΡΠΉ ΡΠ΅ΡΠΌΠ΅Π½Ρ ΠΏΠ»Π°Π·ΠΌΠΈΠ½. ΠΠ°ΡΡΡΠ΅Π½ΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° Π²Π΅Π΄ΡΡ ΠΊ ΡΠ³Π½Π΅ΡΠ΅Π½ΠΈΡ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΠ·Π° ΠΈ ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡ ΠΊ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² [49, 132].
ΠΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ Π±ΡΠ»ΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ, ΠΏΡΠΈ ΡΡΠΎΠΌ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Π½Π΅ Π±ΡΠ»ΠΈ [43]. ΠΠ΅ΠΆΠ΄Ρ ΡΠ΅ΠΌ, ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΠΊΡΠ°ΡΠ½ΠΎΠΉ Π²ΠΎΠ»ΡΠ°Π½ΠΊΠΈ (Π‘ΠΠ), ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈΠ· ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ, ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ², ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π· ΠΊΠΎΡΠΎΡΡΡ Π½Π΅ ΡΡΠ΅Π½ [126]. ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ, ΡΡΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ ΠΈΠΌΠ΅Π΅ΡΡΡ ΡΠ³Π½Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΠ·Π°, ΠΊΠΎΡΠΎΡΠΎΠ΅ ΠΏΡΠΎΡΠ΅ΠΊΠ°Π΅Ρ ΠΏΠΎ Π΄Π²ΡΠΌ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ°ΠΌ [132]. ΠΡΠΎ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΡΠΊΠ°Π½Π΅Π²ΠΎΠ³ΠΎ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡΠ° ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΈ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ° Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡΠ° ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° 1 Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ. ΠΡΠΎ Π²Π΅Π΄ΡΡ ΠΊ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΈ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π²ΡΠ΅Π³ΠΎΡΡ ΠΏΠ»Π°Π·ΠΌΠΈΠ½Π°. ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½Π½ΡΠ΅ Gonzalez-Gronow [43] Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΌΠΎΠ³ΡΡ ΡΠ»ΡΠΆΠΈΡΡ Π΅ΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠΌ ΡΠ³Π½Π΅ΡΠ΅Π½ΠΈΡ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΠ·Π° ΠΈ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ. Π ΡΡΠΎΠΉ ΡΠ²ΡΠ·ΠΈ, Π²ΠΎΠΏΡΠΎΡ ΠΎ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΠΎΠ»ΠΈ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΏΡΠΈ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΎΡΡΠ°ΡΡΡΡ ΠΎΡΠΊΡΡΡΡΠΌ.
ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠ΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΡ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌ ΡΠ²ΡΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ ΠΈ Π±Π΅Π»ΠΊΠ°ΠΌ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠΈΠ±ΡΠΈΠ½ΠΎΠ»ΠΈΠ·Π° Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π΅ΠΈΠ·Π²Π΅ΡΡΠ½Ρ. Π‘ΡΠ΅Π΄ΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ ΠΏΡΠΈΡΠΈΠ½ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ Ρ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΡΠ²ΠΎΠΉΡΡΠ² Π°ΡΡΠΎΠ°Π½ΡΠΈΠ³Π΅Π½Π° ΠΎΠ±ΡΡΠΆΠ΄Π°Π΅ΡΡΡ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΡ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠ΅ΠΊ Π½Π°ΡΠΈΠ²Π½ΠΎΠΉ ΠΌΠΎΠ»Π΅ΠΊΡΠ»Ρ [112] ΠΈ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΠΈΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠ΅ΡΠ΅ΠΊΡΡΡΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΏΠΈΡΠΎΠΏΠ°ΠΌΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΈ ΠΏΡΠΎΡΡΠΎΠΌΠ±ΠΈΠ½Π° [99, 100]. ΠΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, ΠΈΡ ΠΏΠ΅ΡΠ΅ΠΊΡΡΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ΄Π΅Π»Π°ΡΡ Π²ΡΠ±ΠΎΡ Π² ΠΏΠΎΠ»ΡΠ·Ρ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈΠ· Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ.
Π€Π°ΠΊΡΠΎΡΠΎΠΌ, ΠΊΠΎΡΠΎΡΡΠΉ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΎΠ³ΡΠ°Π½ΠΈΡΠΈΠ²Π°Π΅Ρ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ, ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½ΡΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠ»Π° ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ΠΎΠ² Π² ΡΡΠΈΡ ΡΠ°Π±ΠΎΡΠ°Ρ ΡΠΈΠ»ΡΠ½ΠΎ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΎ.
Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ, Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ, ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΡ ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΠΎΠ»ΠΈ Π² Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°.
Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ.
ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ, ΠΈ ΠΈΡ Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° ΠΏΡΠΎΡΠ΅ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° in vitro.
ΠΠ°Π΄Π°ΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ.
1. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΌΠ΅ΡΠΎΠ΄Π° Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ Π°Π½ΡΠΈΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄Π½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ (ΠΠ€Π‘).
2. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ²ΠΎΠΉΡΡΠ² Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π».
3. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ Π½Π° ΠΏΡΠΎΡΠ΅ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° in vitro.
ΠΠ°ΡΡΠ½Π°Ρ Π½ΠΎΠ²ΠΈΠ·Π½Π°.
Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π²ΡΠ΄Π΅Π»Π΅Π½Ρ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½Ρ ΠΊ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΠΎ-Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ ΡΠΏΠΈΡΠΎΠΏΠ°ΠΌ ΠΌΠΎΠ»Π΅ΠΊΡΠ»Ρ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°. ΠΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΠΎΠ±Π»Π°Π΄Π°ΡΡ ΠΏΠ΅ΡΠ΅ΠΊΡΡΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½Ρ ΠΈ ΠΏΡΠΎΡΡΠΎΠΌΠ±ΠΈΠ½Ρ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°ΡΡ ΡΠΊΠΎΡΠΎΡΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Glu-, //^-ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΡΡΠΎΠΊΠΈΠ½Π°Π·ΠΎΠΉ ΠΈΠ· ΠΌΠΎΡΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°.
ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ.
Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½ ΠΌΠ΅ΡΠΎΠ΄ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΠ³ ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘. ΠΠΏΠ΅ΡΠ²ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘ ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ. ΠΡΡΠΈΠ½Π½Π°Ρ Ρ ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΡ Π½Π° ΡΠΎΡΠ±Π΅Π½ΡΠ΅ ΠΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½-Π‘Π΅ΡΠ°ΡΠΎΠ·Π° ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΎΡΠ½ΠΎΠ²ΠΎΠΉ Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ.
Π²ΡΠ²ΠΎΠ΄Ρ.
Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½ ΠΌΠ΅ΡΠΎΠ΄ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» IgG ΠΊ ΠΠ³ ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΠΎΠ»ΡΡΠ°ΡΡ Π²ΡΡΠΎΠΊΠΎΠΎΡΠΈΡΠ΅Π½Π½ΡΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ Π² ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΈΠ²Π½ΡΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π°Ρ .
Π‘ ΠΏΠΎΠΌΠΎΡΡΡ Π°ΡΡΠΈΠ½Π½ΠΎΠΉ Ρ ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π‘ΠΠ Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ ΠΠ€Π‘ ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΡΡ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³. Π ΡΠ°ΠΌΠΊΠ°Ρ ΡΠ²Π΅ΡΠ΄ΠΎΡΠ°Π·Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΠΠ€Π ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΠ΅ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½Ρ ΠΊ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ ΡΠΏΠΈΡΠΎΠΏΠ°ΠΌ Π² ΡΠΎΡΡΠ°Π²Π΅ Π»ΠΈΠ·ΠΈΠ½-ΡΠ²ΡΠ·ΡΠ²Π°ΡΡΠΈΡ ΡΠ°ΠΉΡΠΎΠ² ΠΌΠΎΠ»Π΅ΠΊΡΠ»Ρ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°. ΠΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΠ³ ΠΎΠ±Π»Π°Π΄Π°ΡΡ ΠΏΠ΅ΡΠ΅ΠΊΡΡΡΡΠ½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½Ρ ΠΈ ΠΏΡΠΎΡΡΠΎΠΌΠ±ΠΈΠ½Ρ.
ΠΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π»Π° IgG ΠΊ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Ρ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°ΡΡ ΡΠΊΠΎΡΠΎΡΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Glu-, LysΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΠΌΠΎΡΠ΅Π²ΠΎΠΉ ΡΡΠΎΠΊΠΈΠ½Π°Π·ΠΎΠΉ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° Π² ΡΠ΅ΡΡΠ°Ρ in vitro, ΠΈ Π½Π΅ Π²Π»ΠΈΡΡΡ Π½Π° ΡΠΊΠΎΡΠΎΡΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π° ΡΠΊΠ°Π½Π΅Π²ΡΠΌ Π°ΠΊΡΠΈΠ²Π°ΡΠΎΡΠΎΠΌ ΠΏΠ»Π°Π·ΠΌΠΈΠ½ΠΎΠ³Π΅Π½Π°.
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ½ΡΠΈΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄Π½ΡΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ Π² Π°ΠΊΡΡΠ΅ΡΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅. ΠΠΎΠ΄ ΡΠ΅Π΄. ΠΠ°ΠΊΠ°ΡΠ°ΡΠΈΡ Π. Π., Π ΡΡΡΠΎ, 2001, 362 Ρ.
- ΠΡΠ±Π°ΠΈΡΠΎΠ² Π.Π. ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΠ΅ ΠΎΡΠ½ΠΎΠ²Ρ ΡΠ²ΡΡΡΡΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ ΠΈ ΡΡΠΎΠΌΠ±ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ. ΠΠ°Π·Π°Π½Ρ, Π€ΠΠ, 2000, 350 Ρ.
- ΠΠ°ΠΊΡΡΡΠΎΠ² Π.Π., ΠΠ°Π³ΡΠ΅Π±Π΅Π»ΡΠ½ΡΠΉ Π‘. Π. ΠΠ½ΡΠΈΠ³Π΅Π½Π½ΡΠ΅ Π΄Π΅ΡΠ΅ΡΠΌΠΈΠ½Π°Π½ΡΡ Π±Π΅Π»ΠΊΠΎΠ². ΠΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΠΉ ΠΈΠΌΠΌΡΠ½Π½ΡΠΉ ΠΎΡΠ²Π΅Ρ. ΠΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½Π°Ρ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ, 1995, 27, № 5, Ρ. 980−991.
- ΠΠ°Π½ΡΠ΅Π½ΠΊΠΎ Π.Π., ΠΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠΊΠΈΠΉ Π. Π. Π’ΡΠΎΠΌΠ±ΠΎΠ·Ρ Π² ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π., Π‘ΠΏΠΎΡΡ ΠΈ ΠΊΡΠ»ΡΡΡΡΠ°, 1999, 462 Ρ.
- ΠΡΠ°ΠΊΡΠΈΠΊΡΠΌ ΠΏΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΠΎΠ΄ ΡΠ΅Π΄. ΠΠΎΠ½Π΄ΡΠ°ΡΡΠ΅Π²ΠΎΠΉ Π. Π., ΠΡΡΠ°ΠΊΠΎΠ²ΠΎΠΉ Π. Π., ΠΠΎΡΠΎΠ±ΡΡΠ²ΠΎΠΉ Π. Π. Π., ΠΠ·Π΄Π°ΡΠ΅Π»ΡΡΡΠ²ΠΎ ΠΠΠ£, 2001,223 Ρ.
- Π Π΅ΡΠ΅ΡΠ½ΡΠΊ Π’.Π., ΠΠ»Π΅ΠΊΠ±Π΅ΡΠΎΠ²Π° Π. Π‘. ΠΠ½ΡΠΈΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄Π½ΡΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ: ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΡ, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ, ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ, ΠΏΡΠΎΠ³Π½ΠΎΠ·. Π’Π΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡ ΠΈΠ², № 12, Ρ. 74−78.
- Π¨ΠΈΡΡΠΌΠ°Π½ Π€.Π. ΠΠ°ΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΊΡΠΎΠ²ΠΈ. Π‘-ΠΠ±., ΠΠ΅Π²ΡΠΊΠΈΠΉ Π΄ΠΈΠ°Π»Π΅ΠΊΡ, 2000,446 Ρ.
- Abiko Y., Iwamoto Π., Shimizu Π. Plasminogen-plasmin system. J. Biochem., 1968, v. 64, p. 743−750.
- Akimoto Π’., Akama Π’., Kono I., Sumida Π’. Relationship between clinical features and binding domains of anti-prothrombin autoantibodies in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus, 1999, v. 8, p. 761−766.
- Alarcon-Segovia D., Perez-Vazquez M.E., Villa A.R., Drenkard C., Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin. Arthritis Rheum., 1992, v. 21, p. 275−286.
- Aledort L. Inhibitors in hemophilia patients: current status and management. Am. J. Hematol., 1994, v. 47, p. 208−217.
- Algiman M, Dietrich G, Nydegger U.E., Boieldieu D, Sultan Y. Natural antibodies to factor VIII in healthy individuals. Proc. Natl. Acad. Sci. USA, 1992, v. 89, p. 37 953 799.
- Arviex J., Darnige L., Hachulla E., Roussel B. Species specificity of anti-p2 glycoprotein I autoantibodies and its relevance to anticardiolipin antibody quantitation. Thromb. Haemost., 1996, v. 75, p. 725−730.
- Axelsen N.H., Kroll J., Weeke B. Manual of quantitative immunielectrophoresis. Oslo, 1973, 216 p.
- Bick R.L. Acquired circulating anticoagulants. Bick R.L. Disorders of Thrombosis and Hemostasis: Clinical and Laboratory Practice. Chicago, 1992, p. 223−232.
- Binder B.R. Physiology and pathophysiology of the fibrinolytic system. Fibrinolysis, 1995, v. 9 (Suppl. l), p. 3−8.
- Bok R.A., Mangel W.F. Qualitative characterization of the binding of plasminogen to intact fibrin clots, lysine-Sepharose, and fibrin cleaved by plasmin. Biochemistry, 1985, v. 24, p. 3279−3286.
- Carreras L.O., Forastiero R.R., Martinuzzo M.E. Which are the best biological markers of the antiphospholipid syndrome? J. Autoimm., 2000, v. 15, p. 163−172.
- Carreras L.O., Forastiero R.R. Pathogenic role of antiprotein-phospholipid antibodies. Haemostasis, 1996, v. 26 (Suppl.4), p.340−357.
- Castellino F., Powell J. Human plasminogen. Meth. Enzymol., 1981, v. 80, p. 365−378.
- Chase T., Shaw E. Comparison of the esterase activities of trypsin, plasmin and thrombin on guanidinobenzoate esters. Titration of the enzymes. Biochemistry, 1969, v. 5, p. 2210−2219.
- Church W.R., Messier T.L., OuelletteL.A., Potts S. A kringle-specific monoclonal antibody. Hybridoma, 1994, v. 13, p. 423−429.
- Church W.R., Messier T.L. Inhibition of plasminogen activation by monoclonal antibodies to the kringle 5-B chain segment of human plasminogen. Hybridoma, 1991, v. 10, p. 659−672.
- Cugno M., Dominguez M., Cabibbe M., Bisiani G. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Brit. J. Haematol., 2000, v. 108, p. 871−875.
- Cummings H.S., Ploplis V.A., Beals J.M., Castellino F.J. Interspecies cross-reactivity of monoclonal antibodies to various epitopes of human plasminogen. Arch. Biochem. Biophys., 1984, v. 230, p. 306−315.
- Deutsch D.G., Mertz E.T. Plasminogen: purification from human plasma by affinity chromatography. Science, 1970, v. 170, p. 1095−1096.
- Dominguez M., Cacoub P., de la Torre I.G., Piette J. Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
- J. Rheumatol., 2001, v. 28, p. 302−308.
- Esmon C.T. Regulation of blood coagulation. Biochem. Biophys. Acta, 2000, v.1477, p. 349−360.
- Fay P.J., Smudzin T.M. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor Villa. J. Biol. Chem., 1992, v. 267, p. 1 324 613 250.
- Feinstein D.I., Rapaport S.I. Acquired inhibitors of blood coagulation. Prog. Hemost. Thromb., 1972, v. l, p. 75−95.
- Fleck R.A., Rapaport S.I., Rao V.M. Antiprothrombin antibodies and the Lupus Anticoagulant, Blood, 1988, v. 72, p. 512−519.
- Fritzler M.J., Hart D.A., Wilson D., Garcia-de la Torre I. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. J. Rheumatol., 1995, v. 22, p.1688−1692.
- Fritzler M.J., Salazar M. Diversity and origin of rheumatologic autoantibodies. Clin. Microbiol. Rev., 1991, v. 4, p. 256−269.
- Furie B, Furie B.C. The molecular basis of blood coagulation. Cell, 1988, v. 53, p. SOS-SIS.
- Galli M., Barbui T. Antiprothrombin Antibodies: Detection and clinical significance in the antiphospholipid syndrome. Blood, 1999, v. 93, p. 2149−2157.
- Galli M, Comfurius P, Barbui T, Zwaal R.F., Bevers E.M. Anticoagulant activity of 02-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb. Haemost., 1992, v. 68, p. 297−300.
- Gawryl M.S., Hoyer L.W. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood, 1993, v. 82, p. 2425−2461.
- Gilles J.G., Arnout J, Vermylen J, Saint-Remy J-M. Anti-Factor VIII antibodies of hemophilic patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood, 1993, v. 82, p. 2452−2461.
- Gonzalez-Gronow M., Cuchacovich M., Grigg D.M., Pizzo S.V. Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis. J. Mol. Med., 1996, v. 74, p. 463−469.
- Gonzalez-Gronow M., Grenett H E., Fuller G.M., Pizzo S.V. The role of carbohydrate in the function of human plasminogen: comparison of the protein obtained from the molecular cloning and expression in Escherichia coli and COS cells.
- Biochim. Biophys. Acta., 1990, v.1039, p. 269−276.
- Green D, Lechner K. A survey of 215 nonhemophylic patients with inhibitors to factor VIII. Thromb. Haemost., 1981, v. 45, p. 200−203.
- Guilbert B., Dighiero G., Avrameas S. Naturally Occurring Antibodies Against Nine Common Antigens in Human Sera. J. Immunol., 1982, v. 128, p. 2779−2787.
- HashimotoY, Kawamura M, Ichikawa K, Suzuki T, Sumida T. Anticardiolipin antibodies in NZW x BXSB F1 mice: a model of antiphospholipid syndrome.
- J. Immunol., 1992, v. 149, p. 1063−1068.
- Hassouna H.I. Laboratory evaluation of hemostatic disorders. Hematol. Oncol. Clin. North. Am., 1993, v. 7, p. 161−1249.
- Herbert K.F., Teitel J.M., Cheung To, Sam K.P. Hypofibrinolysis in patients with hypercoagulability: the roles of urokinase and of plasminogen activator inhibitor. Am. J. Hematol., 1993, v. 44, p. 260−265.
- Herbst K.D., Rapaport S.I., Kenoyer D.G., Swtanton W, Feinstein D.I. Syndrome of an acquired inhibitor to factor VIII responsive to cyclophosphamide and prednisone. Ann. Intern. Med., 1981, v. 95, p. 575−578.
- Holvoet P., Lijnen H.R., Collen D. A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Eur. J. Biochem., 1986, v. 157, p. 65−69.
- Hoyer L.W. Immunochemical properties of factor VIII and factor IX inhibitors. Blood Coagul. Fibrinol., 1991, v. 21, p. 11S-15S.
- Hughes G.R., Harris N.N., Gharavi A.E. The anticardiolipin syndrome. J. Rheumatol., 1986, v. 13, p. 486−489.
- Hunt J.E., Krilis S.A. The fifth domain of P2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies.
- J. Immunol., 1994, v. 152, p. 653−659.
- Ichikawa K, Khamashta M.A., Koike T, Hughes G.R. P2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum., 1994, v. 37, p.1453−1461.
- Inane N., Radway-Bright E.L., Isenberg D.A. P2-Glycoprotein I and Anti-P2-Glycoprotein I Antibodies: Where are we now? Brit. J. Rheumatol., 1997, v. 36, p. 1247−1257.
- Israels S.J., Israels E.D. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am. J. Pediatr. Hematol. Oncol., 1994, v. 16, p. 249−254.
- Kato H, Enjyoji K. Amino acid sequence and location of the disulfide bonds in bovine p2-glycoprotein I: the presence of five Sushi domains. Biochemistry, 1991, v. 30, p. 11 687−11 694.
- Kessler C.M. An introduction to factor VIII inhibitors: the detection and quantitation. Am. J. Med., 1991, v. 91, p. 1S-5S.
- Kruger N.J. The Bradford method for protein quantitation. Walker J.M. Basic protein and peptide protocols. New Jersey, 1994, p. 9−15.
- Lacroix-Desmazes S., Kaveri S.V., Mouthon L., Ayouba A. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J. Immunol. Meth., 1998, Vol. 216, p. 117−137.
- Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, v. 227, p. 680−685.
- Lamphear B.J., Fay P.J. Proteolytic interactions of factor IXa with human factor VIII and factor Vina. Blood, 1992, v. 80, p. 3120−3126.
- Laurell A.B., Nillson I.M. Hypergamma-globulinaemia circulating anticoagulant, and biologic false-positive Wasserman reaction: a study of 2 cases. J. Lab. Clin. Med., 1957, v. 49, p. 694−707.
- Laver W.G., Air G.M., Webster R.G., Smith-Gill S.J. Epitopes on protein antigens: misconceptions and realities. Cell, 1990, v. 61, p. 553−556.
- Lidar M, Braf A., Givol N., Langevitz P. Anti-insulin antibodies and the natural autoimmune response in systemic lupus erythematosus. Lupus, 2001, v. 10, p.81−86.
- Lijnen R., Van Hoef B., Collen D. On the role of the carbohydrate side chains of human plasminogen in its interaction with a2-antiplasmin and fibrin. Eur. J. Biochem., 1981, v. 120, p. 149−154.
- Lin L., Houng A., Reed G.L. Epsilon amino caproic acid inhibits streptokinase-plasminogen activator complex formation and substrate binding through kringle-dependent mechanism. Biochemistry, 2000, v. 39, p. 4740−4745.
- Lozier J, Takahashi N, Putman F.W. Complete amino acid sequence of human plasma p2-glycoprotein I. Proc. Natl. Acad. Sci. USA, 1984, v. 81, p. 3640−3644.
- Makker S.P. Novel autoantibody to plasminogenand its characterization in Heymann Nephritis. Clin. Immunol. Immunopathol., 1994, v. 72, p. 105−113.
- Mann K.G., Jenny R.J., Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann. Rev. Biochem., 1988, v. 57, p. 915−956.
- Mann K.G., Nesheim M.E., Tracy P.B., Hibbard L.S., Bloom J.S. Assembly of the prothrombinase complex. Biophys. J., 1982, v. 37, p. 106−107.
- Marwaha N., Sarode R., Chauhan A.P., Varma J.S., Dash S. Simultaneous occurrence of factor VIIIC inhibitor and antinuclear antibody in postpartum period. Am. J. Hematol., 1991, v. 37, p. 49−50.
- Mason L.J., Isenberg D.A. Immunopathogenesis of SLE. Bailliere’s Clinical Rheumatol., 1998, v. 12, p. 385−403.
- Matsuura E, Igarashi M, Igarashi Y, Katahira T, Nagae H. Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on P2-glycoprotein I structure recognized by anticardiolipin antibodies. Lupus, 1995, v. 4, S13-S17.
- Matsuura E., Igarashi Y., Yasuda T., Triplett D.A., Koike T. Anticardiolipin antibodies recognize P2-Glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med., 1994, v. 179, p. 457−462.
- McLennan B.D., Raney J.P. The development of a microimmunoadsorbent assay and a microdialysis method for the evaluation of immunoadsorbent efficiency and antibody quantitation. Anal. Biochem., 1985, v. 148, p. 490−497.
- Miles L.A., Plow F. Topography of the high-affinity lysine binding site of plasminogen as defined with a specific antibody probe. Biochemistry, 1986, v.25, p. 6926−6933.
- Munson P.J., Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem., 1980, v.107, p.220−239.
- Natio K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J. Biol. Chem., 1991, v. 226, p. 7353−7358.
- Nimpf J, Wurm H, Kostner G.M. p2-glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP- induced aggregation. Atherosclerosis, 1987, v. 63, p. 109−114.
- Nimpf J, Bevers E. M, Bomans P. H, Till U, Wurm H. Prothrombonase activity of human platelets is inhibited by P2-glycoprotein I. Biochim. Biophys. Acta, 1986, v. 884, p. 142−149.
- Nomura S, Fukuhara S, Komiyama Y, Takahashi H, Matssura E. P2-glycoprotein I and anticardiolipin antibody influence factor Xa generation but not factor Xa binding to platelet-derived microparticles. Thromb. Haemost., 1994, v. 71, p. 526−527.
- Ogawa H., Zhao D., Dlott J., Cameron G. Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvment in antiphospholipid antibody specificities. Am. J. Clin. Pathol., 2000, v. 114, p. 619−628.
- Oosting J.D., Derksen R., Bobbink I., Hackeng T.M. Antiphospholipid antibodies directed against a combination of phospholipids with protrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood, 1993, v. 81, p. 2618−2625.
- Orstavik K.H., Miller C.H. IgG subclass identification of inhibitors to factor IX in hemophilia B patients. Br. J. Haematol., 1988, v. 68, p. 451−454.
- Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell, 1985, v. 41, p. 657−663.
- Paul S., Mei S., Mody B., Eklund S.H. Cleavage of vasoactive intestinal peptide at multiple sites by autoantibodies. J.Biol.Chem., 1991, v. 266, p.16 128−16 134.
- Pengo V., Biasolo A., Brocco T., Tonetto S., Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thrombosis and Haemostasis, 1996, v. 75, p. 721−724.
- Peter J.B., Shoenfeld Y. Autoantibodies. N.Y., 1996, 412 p.
- Pheng-Siew S., Fayle D., Doe W.F., Stephens R.W. Monoclonal antibodies inhibitory to human plasmin. Eur. J. Biochem., 1986, v. 158, p. 537−542.
- Ploplis V.A., Cummings H.S., Castellino F.J. Monoclonal antibodies to discrete regions of human Glu-plasminogen. Biochemistry, 1982, v. 21, p. 5891−5897.
- Ponting C.P., Marshall J.M., Cederholm-Williams S.A. Plasminogen: a structural review. Blood Coagul. Fibrinol., 1992, v. 3, p.605−614.
- Powell J.R., Castellino F.J. Activation of human neo-plasminogen-Val 442 by urokinase and streptokinase and a kinetic characterization of neo-plasmin-Val 442. J. Biol. Chem. 1980, v. 255, p. 5329−5335.
- Puurunen M., Palosuo T., Lassila R., Anttila M. Immunologic and hematologic properties of antibodies to prothrombin and plasminogen in a mouse model. Lupus, 2001, v. 10, p. 108−115.
- Puurunen M., Manttari M., Manninen V., Palosuo T., Vaarala O. Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction. Brit. J. Haematol., 1998, v. 100, p. 374−379.
- Rand J. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. J. Autoimm. 2000, v.15, p.107−111.
- Ray S.K., Putterman C., Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: A paradigm for autoimmune disease. Proc. Natl. Acad. Sci. USA, 1996, v. 93, p. 2019−2024.
- Reen D.J. Enzyme-linked immunosorbent assay (ELISA). Walker J.M. Basic Protein and Peptide Protocols. New Jersey, 1994, p. 461−466.
- Roberts H. R, Elberts M.E. Current management of hemophilia B. Hematol. Oncol. Clin. North. Am., 1993, v. 7, p. 1269−1280.
- Shapiro S.S. The lupus anticoagulant / antiphospholipid syndrome. Annu. Rev.Med., 1996, v. 47, p. 533−53.
- Shapiro S.S., Siegel J.F. Hemorrhagic disorders associated with circulating inhibitors. Rattnof O.D., Forbes C.D. Disorders ofHemostasis. Philadelphia, 1991, p. 245−260,
- Shearin T.V., Pizzo S.V., Gonzalez-Gronow M. Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis, patients. J. Mol. Med., 1997, v. 75, p. 378−385.
- Shi G., Chang B., Chen S., Wu D., Wu H. Function of streptokinase fragments in plasminogen activation. Biochem. J., 1994, v. 304, p. 235−241.
- Shi G., Chang B., Wu D., Wu H. Interaction of immobilized human plasminogen and plasmin with streptokinase. Bioch. Biophys. Res. Com., 1993, v. 195, p. 192−200.
- Shi G, Chang B.H., Hogg P.J., Chesterman C.N. Anticardiopipin antibodies block the inhibition by P2-glycoprotein I of the factor Xa generating activity of platelets. Thromb. Haemost., 1993, v. 70, p. 342−345.
- Shibata S., Harpel P.C., Gharavi A., Rand J., Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antitrombin III-thrombin complexes. Blood, 1994, v. 83, p. 2535−2540.
- Shousboe I. p2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood, 1985, v. 66, p. 1086−1091.
- Sjowall C., Eriksson P., Aimer S., Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren’s syndrome, rheumatoid arthritis or inflammatory bowel disease. J. Autoimm., 2002, v. 19, p. 155−160.
- Strieker R.B., Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J. Rheumatol., 1994, v. 21, p. 350−352.
- Suehisa E, Toku M, Akita N, Fushima R, Takano T. Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto’s disease and bullous pemphigoid. Thromb. Res., 1995, v. 77, p. 63−68^
- Summaria L., Pavlovic B., Sandesara J. An anti-plasminogen antibody preparation that inhibits the activation of human plasminogen but enhances the activator activity of the B-chain-streptokinase complex. Thromb. Res., 1989, v. 54, p. 1−16.
- Tan E.M., Cohen A.S., Fries J.F., Masi A.T. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum., 1982, v. 25, p. 1271−1277.
- Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation influence of o-aminocarboxylic acids. Biochim. Biophys. Acta, 1975, v. 393, p. 55−65.
- Tincani A., Balestrieri G., Spatola L., Cinquini M. Anticardiolipin and anti-p2-glycoprotein I immunoassays in the diagnosis of the antiphospholipid syndrome. Clin. Exp. Rheumatol., 1998, v. 16, p. 396−402.
- Tomas J.F., Alberca I., Tabernero M.D., Cordero M. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus. J. Rheumatol., 1998, v. 25, p. 57−62.
- Toole J.J., Knopf J.L., Wozney J.M., Sultzman L.A., Buecker J.L. Molecular cloning of cDNA encoding human antihaemofilic factor. Nature, 1984, v. 312, p. 342−347.
- Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am. J. Hematol., 1995, v. 48, p. 34−39.
- Triplett. D.A. Use of the dilute Russell Viper Venom Time (dRVVT): its importance and pitfalls. J. Autoimm., 2000, v. 15, p.173−178.
- Triplett D.A. Antiphospholipid-protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment).Haemostasis, 1996, v. 26 (Suppl. 4), p. 358−367.
- Triplett D.A. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb. Haemost., 1995, v. 78, p. 1−31.
- Tsakiris D.A., Marbet G.A., Makris P.E., Settas L., Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb. Haemostasis, 1989, v. 61, p.175−177.
- Vaarala O., Puurunen M., Manttari M., Manninen V. Antibodies to prothrombin imply a risk of miocardial infarction in middle-aged men. Thromb. Haemost., 1996, v. 75, p. 456−459.
- Vehar G.A., Keyt B., Eaton D, Rodriguez H, O’Brien D.P. Structure of human factor VIII. Nature, 1984, v. 312, p. 337−342.
- Vehar G.A., Davie E.W. Preparation and purification of bovine factor VIII (antihemofilic factor). Biochemistry, 1980, v. 19, p. 401−410.
- Voss A., Jacobsen S., Heegaard N.H.H. Association of p2-glycoprotein I IgG and IgM antibodies with thrombosis and thrombocytopenia. Lupus, 2001, v.10, p. 533−538.
- Wachtfogel Y.T., DeLa Cadena R.A., Colman R.W. Structural biology, cellular interactions and pathophysiology of the contact system. Thromb. Res., 1993, v. 72, p. 1−21.
- Westermeier R. Electrophoresis in practice. N.Y., 2001,349 p.
- Widsom G.B. Protein bloting. Walker J.M. Basic protein and peptide protocols. New Jersey, 1994, p. 207−214.
- Yang C.D., Chen S.L., Pei J., Xue F. The fifth domain of b2-glycoprotein 1 contains antigenic epitopes recognized by anticardiolipin antibodies derived from patients with the antiphospholipid syndrome. APLAR J.Rheumatol., 1997, v. 1, p. 96−100.